JPWO2020249003A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020249003A5 JPWO2020249003A5 JP2021573591A JP2021573591A JPWO2020249003A5 JP WO2020249003 A5 JPWO2020249003 A5 JP WO2020249003A5 JP 2021573591 A JP2021573591 A JP 2021573591A JP 2021573591 A JP2021573591 A JP 2021573591A JP WO2020249003 A5 JPWO2020249003 A5 JP WO2020249003A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- cancer
- antigen
- antibody
- molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004169 proteins and genes Human genes 0.000 claims 14
- 108090000623 proteins and genes Proteins 0.000 claims 14
- 239000012634 fragment Substances 0.000 claims 8
- 102000003814 Interleukin-10 Human genes 0.000 claims 6
- 108090000174 Interleukin-10 Proteins 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 229940076144 interleukin-10 Drugs 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 2
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102000015696 Interleukins Human genes 0.000 claims 1
- 108010063738 Interleukins Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 208000000185 Localized scleroderma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010027982 Morphoea Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010033647 Pancreatitis acute Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 208000024340 acute graft versus host disease Diseases 0.000 claims 1
- 201000003229 acute pancreatitis Diseases 0.000 claims 1
- 208000004631 alopecia areata Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 208000012934 primary antiphospholipid syndrome Diseases 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2019/090494 | 2019-06-10 | ||
| CN2019090494 | 2019-06-10 | ||
| PCT/CN2020/095354 WO2020249003A1 (en) | 2019-06-10 | 2020-06-10 | Antibody-interleukin fusion protein and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022537515A JP2022537515A (ja) | 2022-08-26 |
| JP2022537515A5 JP2022537515A5 (https=) | 2023-06-19 |
| JPWO2020249003A5 true JPWO2020249003A5 (https=) | 2023-06-19 |
Family
ID=73781610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021573591A Pending JP2022537515A (ja) | 2019-06-10 | 2020-06-10 | 抗体－インターロイキン融合タンパク質および使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220306713A1 (https=) |
| EP (1) | EP3980067A4 (https=) |
| JP (1) | JP2022537515A (https=) |
| CN (1) | CN114599390A (https=) |
| CA (1) | CA3143218A1 (https=) |
| WO (1) | WO2020249003A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4126965A4 (en) * | 2020-05-14 | 2024-10-02 | Elixiron Immunotherapeutics (Hong Kong) Limited | ANTI-PD-L1 ANTIBODIES AND ANTI-PD-L1/IL10 FUSION PROTEINS |
| IL305758A (en) * | 2021-03-10 | 2023-11-01 | Immunowake Inc | Immunomodulatory compounds and their uses |
| CN115838424A (zh) * | 2021-09-22 | 2023-03-24 | 上海康岱生物医药技术股份有限公司 | 靶向tigit的单克隆抗体 |
| CN118434759A (zh) * | 2021-10-10 | 2024-08-02 | 安立玺荣生医(香港)有限公司 | 用抗-pd-l1/il-10融合蛋白治疗疾病的方法 |
| WO2023078245A1 (zh) * | 2021-11-02 | 2023-05-11 | 广东菲鹏制药股份有限公司 | Il10单体融合蛋白及其应用 |
| CN116063547A (zh) * | 2022-07-08 | 2023-05-05 | 盛禾(中国)生物制药有限公司 | 一种二聚体融合蛋白及其应用 |
| WO2024131864A1 (zh) * | 2022-12-21 | 2024-06-27 | 广东菲鹏制药股份有限公司 | 一种il-10单体融合蛋白 |
| WO2025077212A1 (zh) * | 2023-10-08 | 2025-04-17 | 广东菲鹏制药股份有限公司 | 抗pd1-il10融合蛋白及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ592420A (en) * | 2008-10-02 | 2012-12-21 | Emergent Product Dev Seattle | Cd86 antagonist multi-target binding proteins |
| EP3068425B1 (en) * | 2013-11-11 | 2021-01-27 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| WO2015117930A1 (en) * | 2014-02-06 | 2015-08-13 | F. Hoffmann-La Roche Ag | Interleukine 10 immunoconjugates |
| KR102524920B1 (ko) * | 2014-07-22 | 2023-04-25 | 아폴로믹스 인코포레이티드 | 항-pd-1 항체 |
| US10435470B2 (en) * | 2014-08-05 | 2019-10-08 | Cb Therapeutics, Inc. | Anti-PD-L1 antibodies |
| US11001631B2 (en) * | 2016-02-05 | 2021-05-11 | Orionis Biosciences BV | Clec9A binding agents |
| CA3079844A1 (en) * | 2017-11-10 | 2019-05-16 | Armo Biosciences, Inc. | Compositions and methods of use of interleukin-10 in combination with immune checkpoint pathway inhibitors |
-
2020
- 2020-06-10 WO PCT/CN2020/095354 patent/WO2020249003A1/en not_active Ceased
- 2020-06-10 JP JP2021573591A patent/JP2022537515A/ja active Pending
- 2020-06-10 CN CN202080055588.4A patent/CN114599390A/zh active Pending
- 2020-06-10 CA CA3143218A patent/CA3143218A1/en active Pending
- 2020-06-10 EP EP20822767.8A patent/EP3980067A4/en not_active Withdrawn
- 2020-06-10 US US17/617,945 patent/US20220306713A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tapia-Galisteo et al. | Bi-and trispecific immune cell engagers for immunotherapy of hematological malignancies | |
| Lou et al. | Antibody variable region engineering for improving cancer immunotherapy | |
| JP2022177097A (ja) | ヘテロ二量体多重特異性抗体フォーマット | |
| Nuñez-Prado et al. | The coming of age of engineered multivalent antibodies | |
| JP2022159548A5 (https=) | ||
| Feldmann et al. | Novel humanized and highly efficient bispecific antibodies mediate killing of prostate stem cell antigen-expressing tumor cells by CD8+ and CD4+ T cells | |
| JP2020103301A5 (https=) | ||
| JP2021502810A5 (https=) | ||
| Takemura et al. | Construction of a diabody (small recombinant bispecific antibody) using a refolding system | |
| JP2021102633A5 (https=) | ||
| RU2017145150A (ru) | Антитело против pdl-1, его фармацевтическая композиция и применение | |
| JP2020531043A5 (https=) | ||
| RU2017115315A (ru) | Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения | |
| JP2022105495A5 (https=) | ||
| JP2019532619A5 (https=) | ||
| JP2020534830A5 (https=) | ||
| JP2013502913A5 (https=) | ||
| JP2013227339A5 (https=) | ||
| Asano et al. | Domain order of a bispecific diabody dramatically enhances its antitumor activity beyond structural format conversion: the case of the hEx3 diabody | |
| JPWO2019005638A5 (https=) | ||
| ES3036457T3 (en) | A cd33-, cd16- and cd123-specific single chain triplebody | |
| CN115461373A (zh) | 密蛋白18.2的抗体及其用途 | |
| JPWO2020249003A5 (https=) | ||
| EP4327823A1 (en) | Anti-cldn4/anti-cd137 bispecific antibody | |
| JP2016529213A5 (https=) |